Lancet 377:19291937 Creager MA, Olin JW, Belch JJ, Moneta GL, Henry TD, Rajagopalan S, Annex BH, Hiatt WR (2011) Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication
BPC-157: Reported Observations and Safety Considerations Due to the lack of FDA-approved human clinical trials, the safety profile of BPC-157 has not been fully established
Vitamins & Hormones
You may be advised on hydration, monitoring how you feel, and what to do if you notice any unexpected reaction
Vial Size BAC Water Added Concentration 10-Unit Dose 80 mg 2 mL 40 mg/mL 4 mg blend To reconstitute, aim the bacteriostatic water down the inside wall of the vial rather than directly onto the powder pellet, then gently swirl until fully dissolved
The FDA's 2024 review found no published human pharmacokinetic study that formally characterized the subcutaneous route, so these amounts are anecdotal rather than an approved clinical protocol